Mink Therapeutics Inc (INKT) - Net Assets
Based on the latest financial reports, Mink Therapeutics Inc (INKT) has net assets worth $-14.03 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.62 Million) and total liabilities ($23.64 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Mink Therapeutics Inc (INKT) strategic asset index to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-14.03 Million |
| % of Total Assets | -145.9% |
| Annual Growth Rate | N/A |
| 5-Year Change | -159.84% |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Mink Therapeutics Inc - Net Assets Trend (2019–2025)
This chart illustrates how Mink Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Mink Therapeutics Inc stock valuation.
Annual Net Assets for Mink Therapeutics Inc (2019–2025)
The table below shows the annual net assets of Mink Therapeutics Inc from 2019 to 2025. Also explore net asset growth rate of Mink Therapeutics Inc to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-14.23 Million | +27.36% |
| 2024-12-31 | $-19.59 Million | -8.48% |
| 2023-12-31 | $-18.06 Million | -4399.21% |
| 2022-12-31 | $-401.30K | -101.69% |
| 2021-12-31 | $23.78 Million | +144.13% |
| 2020-12-31 | $-53.87 Million | -48.28% |
| 2019-12-31 | $-36.33 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mink Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12017980100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $48.00 | % |
| Other Comprehensive Income | $-718.92K | % |
| Other Components | $143.17 Million | % |
| Total Equity | $-14.23 Million | 100.00% |
Mink Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Mink Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sunsuria Bhd
KLSE:3743
|
$60.73 Million |
|
Bonus Biogroup
TA:BONS
|
$60.74 Million |
|
EasyJet PLC
LSE:EZJ
|
$60.76 Million |
|
Thinkific Labs Inc
TO:THNC
|
$60.76 Million |
|
Talphera Inc.
NASDAQ:TLPH
|
$60.72 Million |
|
Jade Gas Holdings Ltd
AU:JGH
|
$60.69 Million |
|
Isbir Sentetik Dokuma Sanayi AS
IS:ISSEN
|
$60.64 Million |
|
HSS Engineers Bhd
KLSE:0185
|
$60.64 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mink Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -19,585,882 to -14,227,659, a change of 5,358,223.
- Net loss of 12,494,260 reduced equity.
- New share issuances of 14,454,941 increased equity.
- Other comprehensive income decreased equity by 87,340.
- Other factors increased equity by 3,484,882.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-12.49 Million | -87.82% |
| Share Issuances | $14.45 Million | +101.6% |
| Other Comprehensive Income | $-87.34K | -0.61% |
| Other Changes | $3.48 Million | +24.49% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Mink Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $-15.09 | $11.97 | x |
| 2020-12-31 | $-16.28 | $11.97 | x |
| 2021-12-31 | $7.10 | $11.97 | x |
| 2022-12-31 | $-0.12 | $11.97 | x |
| 2023-12-31 | $-5.25 | $11.97 | x |
| 2024-12-31 | $-5.07 | $11.97 | x |
| 2025-12-31 | $-3.33 | $11.97 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mink Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-18.15%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 0.00% | -3451.46% | 0.53x | 0.00x | $-20.17 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.85 Million |
| 2021 | -127.07% | 0.00% | 0.00x | 1.69x | $-32.59 Million |
| 2022 | 0.00% | -1.03% | 125.97x | 0.00x | $-27.95 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-20.65 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.83 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-11.07 Million |
Industry Comparison
This section compares Mink Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $249,490,347
- Average return on equity (ROE) among peers: -108.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mink Therapeutics Inc (INKT) | $-14.03 Million | 0.00% | N/A | $60.73 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $120.41 Million |
| Abcellera Biologics Inc (ABCL) | $1.06 Billion | -15.42% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $1.80 Million | -188.89% | 0.33x | $307.08 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $1.57 Billion |
| Arbutus Biopharma Corp (ABUS) | $101.97 Million | -62.52% | 0.34x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $1.25 Million | -621.32% | 5.21x | $28.25 Million |
| Abivax SA American Depositary Shares (ABVX) | $25.93 Million | -163.70% | 3.21x | $9.34 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $1.23 Billion | 31.86% | 0.27x | $4.73 Billion |
About Mink Therapeutics Inc
MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical tr… Read more